The WVU Rockefeller Neuroscience Institute (RNI) is providing patients greater statewide and regional access to a ...

The WVU Rockefeller Neuroscience Institute is providing patients greater statewide and regional access to a groundbreaking ...

New research suggests Alzheimer's drugs may improve cognition by increasing Aβ42 levels rather than just reducing plaques, ...

The U.S. Food and Drug Administration (FDA) recently granted accelerated approval of a treatment for adults with metastatic ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

One year earlier, in June 2021, the US Food and Drug Administration had approved aducanumab, an antibody-targeting beta-amyloid, as a treatment for Alzheimer's, even though the data supporting its use ...

In November 2020, an FDA advisory panel of experts voted against the approval of a monoclonal antibody called aducanumab. A major concern with aducanumab was the frequency of side-effects ...

In this issue of EMBO Molecular Medicine, Sun and colleagues report the development of a novel therapeutic approach, and preclinical proof-of-concept evidence of its efficacy, for Autosomal Dominant ...

In a clinical study, 16 radiologists read 199 retrospective MRI scans from the aducanumab Phase 2 and 3 trials either with or without the assistance of icobrain aria. The radiologists had an average ...

The Schmitts agreed to receive a monthly infusion of Aducanumab, which is based on the same principle as Leqembi: It is an antibody, in this case from the U.S. biotechnology company Biogen.

An advisory committee to the Ministry of Health, Labour and Welfare (MHLW) has declined to approve Aduhelm (aducanumab), saying the data from its two main clinical trials is hard to interpret ...

Daniel Gibbs, 72, is a retired neurologist in the U.S., who has early stage Alzheimer's dementia. He spent 25 years caring ...